Complement can be produced locally or systemically and is a major link between infection and local or systemic inflammatory diseases, such as periodontitis or sepsis, respectively. However, little is known about local mechanisms that disrupt mucosal tissue-microbe homeostasis and set the stage for unwarranted complement activation. In this regard, periodontitis represents an attractive study model, as it is readily accessible for obtaining both microbial and host tissue samples to longitudinally investigate local inflammatory mechanisms. This highly prevalent disease (>47% of US adults) is initiated by a dysbiotic microbiota, leads to inflammatory destruction of tooth-supporting bone, and adversely affects systemic health in its severe form (8.5% of US adults). Periodontitis therefore urgently requires innovative treatments. The overarching concept in Project 3 of this POl is that complement is crucially and centrally involved in the initiation and amplification of destructive local inflammation in periodontitis through cross-talk interactions with the microbiota and other inflammatory pathways;hence, it represents a prime target for therapeutic intervention. Experiments have been designed to dissect the mechanisms of complement involvement in local tissue regulation of interieukin-17, a key cytokine produced by innate and adaptive immune cells and mediating inflammation and bone loss in periodontitis (Aim 1). On the basis of preliminary studies and those to be performed in Aim 1, appropriate complement inhibitors (Core B &Project 1) will be tested for their efficacy in treating periodontal inflammation and bone loss in non-human primates (Aim 2), a disease that shares key clinical and immunohistological features with human periodontitis. Local inflammation in this model will be investigated at the clinical, histological, and cellular/molecular level in a longitudinal approach that will also include periodic sampling of the periodontal biofilm to monitor complement-dependent dysbiosis. The C5a receptor (C5aR), a crucial target of microbial immune subversion leading to dysbiosis, and C3, required for the amplification of inflammation by the dysbiotic microbiota, will serve as initial targets of therapeutic intervention. Moreover, using a panel of pathway-specific inhibitors, we will dissect the initiation mechanism(s) leading to C3 activation and other complement pathways that may contribute to disease pathogenesis. Complement-specific drugs have already undergone successful safety trials, and promising interventions established in this project have potential for rapid translation to the clinic. Our longterm objective is to apply the mechanistic insights gained from studying local complement inflammation to the treatment of local infection-driven inflammatory diseases.

Public Health Relevance

Periodontitis is a prevalent local inflammatory disease that may cause tooth loss and have an adverse impact on systemic health. The objective of this proposal is to dissect the mechanisms whereby the complement system precipitates periodontitis and apply rational therapeutic intervention in a non-human primate model using appropriate complement inhibitors. This study is also expected to facilitate the development of innovative treatment modalities for other local inflammatory diseases at mucosal sites.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-ESB-I (S1))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Pennsylvania
United States
Zip Code
Schmidt, Christoph Q; Harder, Markus J; Nichols, Eva-Maria et al. (2016) Selectivity of C3-opsonin targeted complement inhibitors: A distinct advantage in the protection of erythrocytes from paroxysmal nocturnal hemoglobinuria patients. Immunobiology 221:503-11
Blatt, Adam Z; Saggu, Gurpanna; Kulkarni, Koustubh V et al. (2016) Properdin-Mediated C5a Production Enhances Stable Binding of Platelets to Granulocytes in Human Whole Blood. J Immunol 196:4671-80
Mastellos, Dimitrios C; Reis, Edimara S; Yancopoulou, Despina et al. (2016) From orphan drugs to adopted therapies: Advancing C3-targeted intervention to the clinical stage. Immunobiology 221:1046-57
Hajishengallis, George; Lambris, John D (2016) More than complementing Tolls: complement-Toll-like receptor synergy and crosstalk in innate immunity and inflammation. Immunol Rev 274:233-244
Lindorfer, Margaret A; Cook, Erika M; Reis, Edimara S et al. (2016) Compstatin Cp40 blocks hematin-mediated deposition of C3b fragments on erythrocytes: Implications for treatment of malarial anemia. Clin Immunol 171:32-35
Maekawa, Tomoki; Briones, Ruel A; Resuello, Ranillo R G et al. (2016) Inhibition of pre-existing natural periodontitis in non-human primates by a locally administered peptide inhibitor of complement C3. J Clin Periodontol 43:238-49
Hajishengallis, George; Hajishengallis, Evlambia; Kajikawa, Tetsuhiro et al. (2016) Complement inhibition in pre-clinical models of periodontitis and prospects for clinical application. Semin Immunol 28:285-91
Ricklin, Daniel; Reis, Edimara S; Lambris, John D (2016) Complement in disease: a defence system turning offensive. Nat Rev Nephrol 12:383-401
Hajishengallis, George; Moutsopoulos, Niki M (2016) Role of bacteria in leukocyte adhesion deficiency-associated periodontitis. Microb Pathog 94:21-6
Wang, Junxiang; Wang, Lu; Xiang, Ying et al. (2016) Using an in vitro xenoantibody-mediated complement-dependent cytotoxicity model to evaluate the complement inhibitory activity of the peptidic C3 inhibitor Cp40. Clin Immunol 162:37-44

Showing the most recent 10 out of 186 publications